One of those is its Covid-19 vaccine which went from a concept in CEO Stephane Boucel’s mind to Phase I trials in a couple of months. Its Phase II trials are expected to begin “any day.” Phase III trials on tens of thousands of subjects are expected to start in July. If Moderna’s vaccine can safely produce enough antibodies to halt the spread of the Covid-19 causing virus, its shares are a bargain. Next Steps For Moderna’s Covid-19 Vaccine CandidateModerna will conduct Phase II and Phase III trials in the next few months. Between 2017 and 2019, Moderna’s cash used in operations increased 39% from $331 million to $459 million, according to its 10K.

Source: Forbes May 27, 2020 19:23 UTC